Nexsen Lands First Asian Hospital Partner in IHH’s $27B Healthcare Network
Nexsen secures first hospital partner in Asia with GHK-IHH collaboration
Nexsen Limited (ASX: NXN) has signed a binding term sheet with GHK Hospital Limited, a subsidiary of IHH Healthcare Berhad, securing its first hospital-based validation partner in Asia. GHK owns Gleneagles Hospital Hong Kong, a 500-bed multi-specialty private tertiary hospital and private teaching hospital with The University of Hong Kong as its exclusive partner. The signing ceremony was held at the Asia Summit on Global Health and witnessed by H.E. Mr Scott Dewar, Australian Ambassador to the People’s Republic of China.
IHH Healthcare carries an approximate market capitalisation of AU$27 billion and operates 190 healthcare facilities, including 89 hospitals, clinics, and ambulatory care centres, across 10 countries. For Nexsen, the collaboration represents a critical bridge between product development and real-world clinical adoption in North Asia.
When big ASX news breaks, our subscribers know first
What the partnership framework covers
The collaboration framework spans four core workstreams:
- Clinical validation of Nexsen’s point-of-care tests in relevant patient populations at GHK
- Real-world data generation to inform clinical workflows and care pathways
- Price point and reimbursement feasibility assessment across Hong Kong and IHH’s North Asia network
- Joint R&D, grant applications, and co-development of future diagnostic products
The framework also covers joint educational and training activities to support appropriate product utilisation by clinicians and other healthcare professionals.
Initial diagnostic activities are expected to focus on Group B Streptococcus (StrepSure®) and Kidney Function diagnostics, targeting Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD). The parties intend to develop the framework into one or more definitive agreements within six months.
The framework is explicitly designed to establish the clinical evidence base, pricing considerations, reimbursement understanding, and clinician familiarity required to support potential future adoption of Nexsen’s diagnostics by GHK and its affiliated entities in North Asia.
Managing Director, Mark Muzzin
“Nexsen has built its platform with world-class research partners to solve diagnostic gaps where faster answers can materially improve clinical decision making. The collaboration with GHK moves that work into a leading hospital environment, giving Nexsen access to specialist clinicians, relevant patient populations and real-world workflows where our rapid diagnostics can be clinically assessed and refined for future adoption. This partnership materially strengthens Nexsen’s ability to execute its Asia-Pacific strategy, providing a critical bridge between product development and real-world adoption across one of the world’s most important healthcare regions.”
Regional Chief Executive Officer of IHH Healthcare North Asia, Dr Kenneth Tsang
“Nexsen’s rapid point-of-care diagnostic platform is a compelling example of the type of innovation that can support more timely clinical decision-making in real-world healthcare settings. The ability to deliver accurate diagnostic insights closer to the patient has the potential to improve workflows, support clinicians and address gaps in care that can impact treatment timing.”
Understanding point-of-care diagnostics and why hospital validation matters
Point-of-care (POC) diagnostics are rapid tests performed at or near the patient, delivering results without sending samples to a central laboratory. In clinical settings, this can mean results in minutes rather than hours or days, enabling faster treatment decisions.
For a diagnostic company like Nexsen, securing hospital-based clinical validation is a significant milestone. Real-world data generated from actual patient populations in accredited hospital settings is required to demonstrate clinical utility, meaning that the test works meaningfully in practice. This evidence base is necessary to support regulatory submissions and unlock reimbursement pathways, the mechanisms by which healthcare systems and insurers agree to pay for a diagnostic product.
Without validated evidence from recognised hospital environments, a diagnostic product cannot progress toward commercial adoption at scale. The GHK collaboration provides Nexsen with direct access to relevant patient populations and established clinical workflows, allowing it to generate precisely this type of evidence within a leading hospital network.
The next major ASX story will hit our subscribers first
The third pillar of Nexsen’s Asia-Pacific strategy
The GHK partnership represents the third foundational element of Nexsen’s Asia-Pacific commercialisation strategy. Notably, each of the three pillars has been secured with non-dilutive funding or institutional co-funding, meaning no equity has been issued to establish these institutional relationships.
| Partner | Type | Location | Key Role | Funding Structure |
|---|---|---|---|---|
| HK$6M IGNITE Grant / GHK Hospital networks | Grant-funded R&D and clinical validation | Hong Kong | Clinical validation of StrepSure®, R&D and manufacturing capability | HK$6M non-dilutive grant |
| UM-Nexsen Joint Research Facility | University R&D hub | Universiti Malaya, Malaysia | Dedicated R&D and commercialisation, food safety diagnostics | Co-funded by Universiti Malaya |
| GHK Hospital Limited (IHH subsidiary) | Hospital validation partner | Hong Kong / North Asia | Clinical validation, real-world data, reimbursement assessment, potential adoption | Collaboration framework (non-dilutive) |
Together, these three initiatives provide Nexsen with an integrated platform spanning research, clinical validation, grant-supported development, manufacturing readiness, and potential future adoption pathways across the Asia-Pacific region.
In parallel, Nexsen’s core regulatory programmes continue to advance, including U.S. clinical site activation and progression toward an FDA 510(k) submission, as previously disclosed.
What comes next
Near-term milestones under the collaboration include:
- Definitive agreements to be progressed within six months of the binding term sheet
- Initial activities focused on clinical validation and real-world assessment of GBS and Kidney Function diagnostics at GHK and affiliated IHH North Asia entities
- Additional diagnostic applications to be scoped progressively as Nexsen’s broader suite of diagnostics advances toward clinical readiness
- Continued pursuit of further partnership and collaboration opportunities across Asia for StrepSure® and Kidney Function diagnostics
Don’t Miss the Next Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button to start receiving real-time coverage across ASX healthcare and beyond.